Please login to the form below

Not currently logged in
Email:
Password:

Gilead sells rights for cancer drug DaunoXome to Galen

First steps into both the US and the oncology markets for Northern Ireland-based pharma firm

Gilead Sciences has sold the rights for its chemotherapy DaunoXome to Northern Ireland-based Galen Pharmaceuticals.

The acquisition, the value of which remains undisclosed, will be the company's first steps into the both the cancer market and the US.

Previously Galen's focus had been on marketing branded and generic prescription medicines in the UK and Ireland in COPD, urology and pain management.

DaunoXome (daunorubicin citrate liposome injection) is an anthracycline chemotherapy used to treat for advanced HIV-associated Kaposi's sarcoma, a type of cancer that usually affects the skin and mouth, and is caused by human herpes virus 8 (HHV8).

Most people living with the virus don't get Kaposi's sarcoma, however, people with weakened immune systems, such as those living with HIV, are more susceptible to it.

President of Galen Mark Scrutton said: "We are delighted that we are now able to supply DaunoXome in the US for the treatment of patients with this devastating disease.

“DaunoXome marks our first step into the oncology arena and this exciting, new acquisition provides us with the opportunity to offer more widely a much-needed therapy for patients with advanced HIV-associated KS."

As well as the US, Galen will market DaunoXome in 12 European countries and Brazil.

Galen's other products include Flotros for incontinence, Saline Steripoules to nebulise COPD and asthma treatments, and Uracyst to repair damaged bladders.

24th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics